Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Omid Farokhzad
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
BIND Biosciences
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
see uploaded document
Development of FcRn-Targeted Nanoparticles for Efficient Oral Delivery of Insulin
Oral administration is considered a more favorable route of administration than injection because of improved convenience and compliance by patients, resulting in improved treatment efficacy. In this project, we will develop a novel nanoparticle delivery system designed to overcome all of the barriers of the gastrointestinal tract and provide efficient oral delivery of biologics such as insulin. This technology may have a significant impact on diseases that are currently limited to injection-based therapies, such as diabetes.
Filed on March 11, 2013.
Tell us what you know about Omid Farokhzad's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Omid Farokhzad filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Omid Farokhzad | Columbia University Health Sciences | Conflict of Interest | Tarveda Therapeutics | $100,000 - $149,999 |
| Omid Farokhzad | Columbia University Health Sciences | Conflict of Interest | Selecta Biosciences | $100,000 - $149,999 |
| Omid Farokhzad | Columbia University Health Sciences | Conflict of Interest | Blend Therapeutics | $100,000 - $149,999 |
| Omid Farokhzad | Brigham and Women's Hospital | Conflict of Interest | BIND Biosciences | $80,000 - $99,999 |
| Omid Farokhzad | Brigham and Women's Hospital | Conflict of Interest | Selecta Biosciences | $80,000 - $99,999 |
| Omid Farokhzad | Brigham and Women's Hospital | Conflict of Interest | Selecta Biosciences | Value cannot be readily determined |
| Omid Farokhzad | Columbia University Health Sciences | Conflict of Interest | Tarveda Therapeutics | Value cannot be readily determined |
| Omid Farokhzad | Columbia University Health Sciences | Conflict of Interest | Selecta Biosciences | Value cannot be readily determined |
| Omid Farokhzad | Columbia University Health Sciences | Conflict of Interest | Blend Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.